Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
[audio:https://www.audiomedica.com/podcasting/ajo_13.8/02.edward_romond.mp3]
Audio Journal of Oncology Podcast AUDIO JOURNAL OF ONCOLOGY: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell...
A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Audio Journal of Oncology Podcast CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms Play Episode Pause Episode Mute/Unmute...
Audio Journal of Oncology Podcast Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent Play Episode Pause Episode Mute/Unmute Episode...
Audio Journal of Oncology Podcast New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia Play Episode Pause Episode Mute/Unmute...
